B Cell Receptor Inhibitor Causes Chronic Lymphocytic Leukemia Remission

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews